Amgen hands off leprosy, TB candidate to Australian non-profit
pharmaphorum
DECEMBER 24, 2020
AMG 634 – a PDE4 inhibitor being investigated for TB and leprosy complication erythema nodosum leprosum (ENL) – is being licensed to Australia’s Medicines Development for Global Health (MDGH), with Amgen surrendering all rights to the drug. million patients every year and causing over a million deaths.
Let's personalize your content